Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2025 08:30 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Enters Commercialization Agreement with Sentynl Therapeutics for Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib), Targeting Ultra-Rare Diseases

Distribution agreement expands access of Nulibry and Zokinvy to 33 countries within CEE, the Mediterranean, and Eurasia
August 26, 2025 05:00 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey

Er-Kim signs distribution agreement with CNX Therapeutics to distribute its portfolio of oncology medications across CEE and Turkey.
June 30, 2025 08:00 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions

Er-Kim has partnered with Immunocore to bring KIMMTRAK (tebentafusp) to patients in Turkey, MENA, Caucasus, and CIS regions
April 30, 2025 06:00 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Er-Kim and Puma Biotechnology sign agreement to commercialize NERLYNX® (neratinib) in select countries in Eastern Europe and Central Asia
April 15, 2025 09:26 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets

Er-Kim signs distribution agreement with Polaris Pharmaceuticals to commercialize Pegargiminase (ADZODI) across 36 markets in the EMEA region
January 14, 2025 13:30 ET | Source: Er-Kim

Er-Kim ogłasza zawarcie wyłącznej umowy dystrybucyjnej z MEDICE Health Family dla Vafseo® w Europie Środkowej i Wschodniej

WARSZAWA, Polska, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Er-Kim, międzynarodowa firma specjalizująca się w komercjalizacji nowych terapii dla firm farmaceutycznych i biofarmaceutycznych, ogłosiła dziś...
January 14, 2025 08:00 ET | Source: Er-Kim

Er-Kim Announces Exclusive Distribution Agreement with the MEDICE Health Family For Vafseo® in Central & Eastern Europe

Er-Kim's partnership will support access of an alternative treatment to improve the lives of people impacted by anemia caused by chronic kidney disease
December 10, 2024 07:00 ET | Source: Er-Kim

Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets

Er-Kim broadens drug distribution for novel rare endocrinology disease therapies in CEE and Eurasian markets
October 15, 2024 07:00 ET | Source: Er-Kim

Er-Kim CEO Cem Zorlular Recognized as a Patient Champion on the 2024 PharmaVoice 100

Cem Zorlular, CEO of Er-Kim recognized as a patient champion in this year's PharmaVoice100
March 05, 2024 09:00 ET | Source: Er-Kim

Er-Kim Selected to Join the World Economic Forum’s New Champions Community

ATHENS, Greece, March 05, 2024 (GLOBE NEWSWIRE) -- Er-Kim, a pharmaceutical company specializing in the commercialization of novel therapies in international markets, announced today it has been...